Ganguli: 90% of drug candidates fail to achieve FDA approval
Surya Ganguli · AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu · Oct 3, 2024 · at 10:44
Surya Ganguli, venture partner at a16z Bio + Health, highlights high attrition rates in pharmaceutical development to show the opportunity for AI.
0:00 / 0:03exact quote · 3.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“90% of drug candidates don't get FDA approval.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Surya Ganguli
Ganguli: Specialized Models Beat Fine-Tuned Foundation Models for Specific Tasks
“You really, I think you're best off with a specialized model trained on the data that's very relevant to the thing, the task you want to solve. Your second best bet is to start with a foundation model that understands the broad space and fine tune it. Again, o…”
Ganguli: FDA-approved drugs target only 800 of roughly 20,000 human genes
“FDA approved drugs they target only 800 of the 20,000 known genes that we have, 20 to 25,000 known genes that we have.”
Ganguli: Evolutionary robustness proves low-dimensional structure controls biological function
“Biological systems have survived for almost four billion years of evolution. They've tolerated all sorts of insults, competition, and so forth, so they're extremely robust. Because they're robust, their function can't depend on all of the details. That means t…”
Ganguli: ESMFold proves language models can learn protein structure from sequences
“I was actually really impressed by ESM fold, this average scale modeling where you could kind of do the same thing that you do for language, but do it for sequences. And then you learn representations that know about the structure of proteins.”